title: Hepatitis C virus: here comes all-oral treatment.
abstract: Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new direct-acting antivirals-sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)-opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.
authors.affiliation: Department of Internal Medicine, Medicine Institute, Cleveland Clinic.
authors.forename: Mohannad
authors.initials: M
authors.lastname: Dugum
authors.forename: Robert
authors.initials: R
authors.lastname: O'Shea
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage*; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D011480:Protease Inhibitors / Q000008:administration & dosage*; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides / Q000008:administration & dosage*; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D011480:Protease Inhibitors; D013449:Sulfonamides; D000069616:Simeprevir; D014542:Uridine Monophosphate; D012321:DNA-Directed RNA Polymerases; D000069474:Sofosbuvir